Journal of Nuclear Science, Engineering and Technology (JONSAT)
In cooperation with the Iranian Nuclear Society

Radiolabeling and Biological Evaluation of 153Sm and 175Yb Zoledronic Acid Complexes

Document Type : Research Paper

Authors

A.R Jalilian
A Aghanejad
A Bahrami Samani
N vahid far
S Moradkhani
M Erfani
Abstract
: Production of bone pain palliation agents is developing increasingly for handling end-stage cancer patients. 153Sm and 175Yb labelled (1-hydroxy-2-imidazol-1-yl-phosphonoethyl) phosphoric acids can be used in bone pain palliation therapy. In this work, 153Sm and 175Yb labelled zoledronates were prepared using the commercial zoledronate ligand and 153SmCl3 and 175YbCl3 at 60ºC, respectively. 153Sm Cl3 and 175YbCl3 were obtained by thermal neutron irradiation (4×1013 n.cm-2s-1) of the natural metal oxide samples. The radiochemical purities were checked by the instant thin layer chromatography (ITLC) and high performance liquid chromatography (HPLC) methods. The stability studies of the final preparations in the presence of human serum, as well as, hydroxyapatite (HA) binding test were performed (>97%). The biodistribution of 153Sm and 153Sm-zoledronate performed in 2-48 h and for 175Yb and the 175Yb-zoledronate performed in 2-96 h post injection in the Syrian mice. The maximum bone uptake for 153Sm-zoledronate was 4% (48 h), while for 175Yb-zoledronate it was 10% (48 h). The complexes demonstrated satisfactory stability in the presence of human serum and the final formulations. However, the complexes are not appropriate for human studies due to the high liver uptake, possibly due to release of free metal from the complex and/or colloid formation.

Keywords

Radiolabeled zoledronic acid
153Sm
175Yb
Bone pain palliation agents
Biodistribution
[1] R.E. Coleman, Clinical features of metastatic bone disease and risk of skeletal morbidity, Clinical Cancer Research., 12 (2006) 6243–6249.
 [2] A. Majkowsk, M. Neves, I. Antunes, A. Bilewicz, Complexes of low energy beta emitters 47Sc and 177Lu with zoledronic acid for bone pain therapy, Applied Radiation and Isotopes., 67 (2009) 11–13.
 [3] L.S. Rosen, D. Gordon, B.S. Antonio, Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double blind, comparative trial, Cancer J., 7 (2001) 377–387.
 
[4] P. Major, A. Lortholary, J. Hon, Zoledronic acid is superior topamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials, J. Clin. Oncol., 19 (2001) 558–567.
 
[5] J. Lin, L. Qiu, W. Cheng, S. Luo, L. Xue, S. Zhang, Development of superior bone scintigraphic agent from a series of 99mTc-labeled zoledronic acid derivatives, Appl. Radiat. Isot., 70(5) (2012) 848–855.
 
[6] M. Nikzad, A.R. Jalilian, S. Shirvani, A. Samani, H. Golchoubian, Production, quality control and pharmacokinetic studies of 177Lu–zoledronate for bone pain palliation therapy, J. Radioanal. Nucl. Chem., (2013).
 
[7] R.B. Firestone, C.M. Baglin, S.Y.F. Chu, Table of Isotopes, 8th Edition,1998 Update with CD-ROM, John Wiley and Sons Inc., New York, USA, ISBN 0471246999.
 
 
 
 
 
[8] A.N. Serafini, S.J. Houston, I. Resche, Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo controlled clinical trial, J. Clin. Oncol., 16(4) (1998) 1574–1581.
 
[9] Boby Mathew, Sudipta Chakraborty, Tapas Das, H.D. Sarma, Sharmila Banerjee, Grace Samuel, Meera Venkatesh, M.R.A. Pillai, 175Yb labeled polyaminophosphonates as potential agents for bone pain palliation, Applied Radiation and Isotopes, 60 (2004) 635–642.
 
[10] IAEA, VIENNA, 2003, IAEA-TECDOC-1340, Manual for reactor produced radioisotopes, ISBN 92-0-101103-2, ISSN 1011-4289,©IAEA (2003).
 
[11] M. Neves, L. Gano, N. Pereira, M.C. Costa, M.R. Costa, M. Chandia, M. Rosado, R. Fausto, Synthesis, characterization and biodistribution of bisphosphonates Sm-153 complexes: correlation with molecular modeling interaction studies, Nucl. Med. Biol., 29 (2002) 329–338.
 
[12] http://www.pharma.us.novartis.com/product/ pi/pdf/Zometa.pdf.
 
[13] Sudipta Chakraborty, Tapas Das, Sharmila Banerjee, Suresh Subramanian, Haladhar Dev Sarma, Meera Venkatesh, 175Yb-labeled hydroxyapatite: a potential agent for use in radiation synovectomy of small joints, Nucl. Med. Bio., 33 (2002) 585–591.
 
[14] X.L. Du, T.L. Zhang, L. Yuan, Y.Y. Zhao, R.C. Li, K. Wang, S.C. Yan, L. Zhang, H. Sun, Z.M. Qian, Complexation of ytterbium to human transferrin and its uptake by K562 cells, Eur. J. Biochem., 269 (2002) 6082–6090.

Home